TRIDERM Triamcinolone Acetonide .25 mg/g Cream — NDC 0316-0165-16 (Billing 00316-0165-16)
This is a package of TRIDERM Triamcinolone Acetonide .25 mg/g Cream from Crown Laboratories, marketed since Mar 1984 and currently FDA-listed.
Other active recalls for Triamcinolone Acetonide (different manufacturers) — 1 · tap to view
Identity & classification
Regulatory identifiers FDA, NLM and CMS codes for this package
- RxCUI (RxNorm): 1014314
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
- RxNorm (NLM RxNav) · catalog refreshed Oct 1, 2026
- Medi-Span GPI (licensed)
- First Databank (licensed) · refreshed Oct 1, 2026
RxNorm drug class
This medicine belongs to the Corticosteroid class.
Where does this data come from?
- RxClass (NLM) · catalog refreshed Oct 1, 2026
Clinical
Triamcinolone topical is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). It is also used as a dental paste to relieve the discomfort of mouth sores. Triamcinolone is in a class of medications called corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching.
Read the full MedlinePlus article ↗- It depends on the product. Injections treat severe allergic conditions, joint inflammation, certain skin problems and eye inflammation. Creams and ointments calm itchy, inflamed sk...
- Injections are given by a healthcare professional. Ointment is applied as a thin film to the affected area two to three times daily. Nasal spray bottles need priming before first u...
- Possible effects include injection site pain, joint swelling, headache, muscle spasms, cough, sinusitis and bruising. People with diabetes may see higher blood sugar. Tell your doc...
- Call right away for signs of an allergic reaction, fever or infection, a very painful and swollen joint, vision changes, or mood changes. Also report black stools, severe stomach p...
Patient education
Supplement & herbal interactions
Some supplements/herbs that may interact with Triamcinolone Acetonide — tap one for details:
Triamcinolone Acetonide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.
Where does this data come from?
- MedlinePlus (NLM) · refreshed Oct 1, 2026
- FDA label on DailyMed · label index refreshed Oct 1, 2026
Ask a licensed pharmacist directly — free, answered by our team.
Pricing
A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.
| Price system | Per g | Per package |
|---|---|---|
| Retail pharmacies payNADAC · weekly | Not in the retail survey — common for institutional, discontinued, or low-volume packs. | |
| Medicaid paysCMS SDUD · 12 mo | No recent Medicaid claims on file for this NDC — rare and low-volume NDCs are suppressed in the public data. | |
| Medicare drug plans payPart D · Q2 2026 | $0.3231 | $146.69 / 454 g |
Where does this data come from?
- CMS NADAC weekly file
- CMS ASP pricing files · refreshed Sep 20, 2026
- CMS Medicaid State Drug Utilization Data · refreshed Oct 2, 2026
- CMS Part D plan pricing files · refreshed Sep 24, 2026
- VA National Acquisition Center price file
Packaging — all sizes for this product
| Package NDC | Description | Marketing start | Marketing end | Status |
|---|---|---|---|---|
| 00316-0165-15 0316-0165-15 Main listing | 1 TUBE in 1 CARTON / 15 g in 1 TUBE | 2015-03-25 | — | Active |
| 00316-0165-16 You're viewing this | 1 JAR in 1 CARTON / 454 g in 1 JAR | 2015-03-25 | — | Active |
| 00316-0165-85 0316-0165-85 | 1 TUBE in 1 CARTON / 85.2 g in 1 TUBE | 2015-03-25 | — | Active |
Pack size FAQ
What quantity is in this package?
What NDC number is used to bill for this package of TRIDERM Triamcinolone Acetonide .25 mg/g Cream?
Therapeutic equivalents
| Product | Labeler | Pack | NADAC/unit | TE | Status | Price vs. this |
|---|---|---|---|---|---|---|
| Triamcinolone Acetonide .25 mg/g 45802-0063-05 | Padagis | 454 g | $0.035 | AT | Availability likely | — |
| Triamcinolone Acetonide .25 mg/g 45802-0054-05 | Padagis | 454 g | $0.047 | AT | Availability likely | — |
| Triamcinolone Acetonide .25 mg/g 00168-0005-80 | E. | 80 g | $0.074 | AT | Availability likely | — |
| triamcinolone acetonide .25 mg/g 00168-0003-15 | E. | 1 tube | $0.120 | AT | Availability likely | — |
| Triamcinolone Acetonide .25 mg/g 00713-0226-15 | Cosette | 1 tube | $0.120 | AT | Discontinued | — |
| Triamcinolone Acetonide .25 mg/g 16714-0985-01 | NorthStar | 1 tube | $0.120 | AT | Availability likely | — |
| Triamcinolone Acetonide .25 mg/g 33342-0327-15 | Macleods | 1 tube | $0.120 | AT | Availability likely | — |
| Triamcinolone Acetonide .25 mg/g 67877-0317-15 | Ascend | 15 g | $0.120 | AT | Availability likely | — |
| Triamcinolone acetonide .25 mg/g 33342-0331-15 | Macleods | 1 tube | $0.239 | AT | Availability likely | — |
| Triamcinolone Acetonide .25 mg/g 00713-0229-15 | Cosette | 1 tube | $0.239 | AT | Availability likely | — |
| Triamcinolone acetonide .25 mg/g 16714-0267-01 | NorthStar | 1 tube | $0.239 | AT | Availability likely | — |
| Triderm .25 mg/gthis 00316-0165-16 | Crown | 1 jar | — | AT | FDA listed | — |
| triamcinolone acetonide .25 mg/g 50090-0293-01 | A-S | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 50090-2658-00 | A-S | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 50090-3704-00 | A-S | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63187-0214-80 | Proficient | 80 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63629-8782-01 | Bryant | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63629-8784-01 | Bryant | 454 g | — | AT | FDA listed | — |
| Triamcinolone acetonide .25 mg/g 68071-2361-01 | NuCare | 15 g | — | AT | FDA listed | — |
| triamcinolone acetonide .25 mg/g 68788-8515-08 | Preferred | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 68788-8899-01 | Preferred | 15 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 71335-2870-01 | Bryant | 454 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 72162-1835-02 | Bryant | 454 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 72162-2334-02 | Bryant | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 76420-0347-15 | Asclemed | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 76420-0360-80 | Asclemed | 80 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 63629-8841-01 | Bryant | 80 g | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 72162-2335-02 | Bryant | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 50090-3802-00 | A-S | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 68788-4148-01 | Preferred | 1 tube | — | AT | FDA listed | — |
| Triamcinolone Acetonide .25 mg/g 50090-0362-00 | A-S | 1 tube | — | AT | FDA listed | — |
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- FDA Orange Book · refreshed Sep 3, 2026
- CMS NADAC weekly file
Availability & generic status
This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.
Where does this data come from?
- FDA Orange Book · refreshed Sep 3, 2026
Inactive Ingredients / Excipients
Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.
💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.
-
UNII 5ZA2S6B08X
Cetyl palmitate is a waxy substance made from natural fats. It works as a binder and thickener to help hold the medicine together and control how it dissolves in your body.
-
UNII T5L8T28FGP
Mineral oil is a clear, odorless liquid derived from crude oil. It acts as a lubricant and emollient in medications, helping pills slide smoothly during manufacturing and aiding moisture retention in topical products.
-
UNII Q504PL8E0V
A waxy emulsifier blend derived from sorbitan and polyethylene glycol. It helps mix oil and water-based ingredients together and is commonly used in creams and ointments to create a smooth, uniform texture.
-
UNII 1VPU26JZZ4
Potassium sorbate is a salt derived from sorbic acid, a naturally occurring preservative. It prevents growth of mold, yeast, and some bacteria, extending the medicine's shelf life.
-
UNII 6DC9Q167V3
Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
-
UNII X045WJ989B
Sorbic acid is a preservative derived from berries that prevents mold, yeast, and bacterial growth in medicines. It keeps the product stable and safe during storage.
-
UNII 506T60A25R
Sorbitol is a natural sugar alcohol derived from glucose. It serves as a sweetener, humectant, and bulking agent in medications to improve taste and help maintain moisture in the product.
-
UNII 059QF0KO0R
Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.
8 inactive ingredients listed in the exact product block matched to this NDC.
Where does this data come from?
ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.- FDA label on DailyMed · label index refreshed Oct 1, 2026
- FDA openFDA NDC Directory · synced Oct 1, 2026
Inactive ingredient FAQ
Are inactive ingredients the same for every manufacturer?
Why might an inactive ingredient be missing?
Can inactive ingredients matter?
Manufacturer & labeler
Where does this data come from?
- FDA openFDA NDC Directory · synced Oct 1, 2026
- Drugs@FDA
Full prescribing information FDA SPL
🎯 Indications and Usage ▾
INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.
⏱️ Dosage and Administration ▾
DOSAGE AND ADMINISTRATION Apply to the affected area as a thin film from two to four times daily for the 0.025% strength and two or three times daily for the 0.1% and 0.5% strength depending on the severity of the condition. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.
⛔ Contraindications ▾
CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.
🤒 Adverse Reactions ▾
ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae, miliaria.
🤰 Pregnancy ▾
Pregnancy Category C Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.
Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.
🧒 Pediatric Use ▾
Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing’s syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenaI (HPA) axis suppression, Cushing’s syndrome, and intracranial hypertension have been reported in pediatric patients receiving topical corticosteroids. Manifestations of adrenal suppression in pediatric patients include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.
Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to pediatric patients should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of pediatric patients.
🆘 Overdosage ▾
OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. (See PRECAUTIONS )
🧬 Clinical Pharmacology ▾
CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, antipruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.
There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man. Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin.
Inflammation and/or other disease processes in the skin increase percutaneous absorption. Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses.
(See DOSAGE AND ADMINISTRATION ). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. Corticosteroids are bound to plasma proteins in varying degrees.
Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.
📦 How Supplied / Storage and Handling ▾
HOW SUPPLIED Triderm (Triamcinolone Acetonide Cream USP), 0.025% is supplied in: 15 grams tube NDC 0316-0165-15 85.2 grams tube NDC 0316-0165-85 454 grams jar NDC 0316-0165-16 Triderm (Triamcinolone Acetonide Cream USP), 0.1% is supplied in: 28.4 grams tube NDC 0316-0170-01 85.2 grams tube NDC 0316-0170-03 Triderm (Triamcinolone Acetonide Cream USP), 0.5% is supplied in: 15 grams tube NDC 0316-0175-15 454 grams jar NDC 0316-0175-16
📦 Storage and Handling ▾
STORAGE Store at room temperature 20 o - 25 o C (68 o - 77 o F) [see USP Controlled Room Temperature]
📋 Description ▾
DESCRIPTION The topical corticosteroids constitute a class of primarily synthetic steroids used as anti-inflammatory and antipruritic agents. Triamcinolone acetonide is a member of this class. Triamcinolone acetonide is chemically pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis-(oxy)]-(11β, 16α)- with the empirical formula C 24 H 31 FO 6 and molecular weight 434.50.
Its structural formula is: Each gram of Triderm (Triamcinolone Acetonide Cream USP), 0.025% contains 0.25 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. Each gram of Triderm (Triamcinolone Acetonide Cream USP), 0.1% contains 1 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.
Each gram of Triderm (Triamcinolone Acetonide Cream USP), 0.5% contains 5 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. TA structure
💬 Information for Patients ▾
Information for the Patient Patients using topical corticosteroids should receive the following information and instructions: 1. This medication is to be used as directed by the physician. It is for external use only.
Avoid contact with the eyes. 2. Patients should be advised not to use this medication for any disorder other than for which it was prescribed.
3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician. 4.
Patients should report any signs of local adverse reactions especially under occlusive dressing. 5. Parents of pediatric patients should be advised not to use tight-fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.
🍼 Nursing Mothers ▾
Nursing Mothers It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.
📄 Carcinogenesis, Mutagenesis, Impairment of Fertility ▾
Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.
📄 Package Label / Principal Display Panel ▾
Triderm (Triamcinolone Acetonide Cream USP), 0.1% tube label NDC 0316-0170-01 Rx Only TRIDERM TM Triamcinolone Acetonide Cream USP, 0.1% 1 oz (28.4 grams) WARNING: Keep Out Of Reach Of Children. For external use only. Not for ophthalmic use. .
Each gram contains: 1 mg Triamcinolone Acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. Usual Dosage: 2 to 3 applications daily. See package insert for full prescribing information.
TO OPEN: Use cap to puncture seal. IMPORTANT: Do not use if seal has been punctured or is not visible. Store at 20 o -25 o C (68 o -77 o F) [see USP Controlled Room Temperature].
Avoid excessive heat. Protect from freezing. See Crimp of tube for Expiration Date and Batch Number.
Manufactured and Distributed by: Crown Laboratories, Inc., Johnson City, TN 37604 0.1% Label
Triderm (Triamcinolone Acetonide Cream USP), 0.1% carton label NDC 0316-0170-01 Rx Only TRIDERM TM Triamcinolone Acetonide Cream USP, 0.1% 1 oz (28.4 grams) WARNING: Keep Out Of Reach Of Children. For External Use Only. Not for Ophthalmic Use.
Each gram contains: 1 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. Directions for puncturing tube seal: Remove cap. Turn cap upside down and place puncture tip onto tube seal: push down until seal is punctured.
Screw cap back on to close. IMPORTANT: Do not use if seal has been punctured or is not visible. Store at 20 o -25 o C (68 o -77 o F) [see USP Controlled Room Temperature].
Avoid excessive heat. Protect from freezing. Manufactured and Distributed by: Crown Laboratories, Inc.
Johnson City, TN 37604 Usual Dosage: 2 to 3 applications daily. See package insert for full prescribing information. See end of carton for batch number and expiration date.
0.1% Carton
Triderm (Triamcinolone Acetonide Cream USP), 0.025% tube label NDC 0316-0165-15 Rx Only TRIDERM CREAM TM Triamcinolone Acetonide Cream USP, 0.025% 15 grams WARNING: Keep out of reach of children For External Use Only Not for Ophthalmic Use Store at 20 o -25 o C (68 o -77 o F) [see USP Controlled Room Temperature] Avoid excessive heat. Protect from freezing. Each gram contains 0.25 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate.
USUAL DOSAGE: 2 or 4 applications daily. See package insert for full prescribing information. TO OPEN: Use cap to puncture seal.
IMPORTANT: Do not use if seal has been punctured or is not visible. See crimp of tube for batch number and expiration date. Manufactured and Distributed by: Crown Laboratories, Inc.
Johnson City, TN 37604 0.025% Label
Triderm (Triamcinolone Acetonide Cream USP), 0.025% carton label NDC 0316-0165-15 Rx Only TRIDERM CREAM TM Triamcinolone Acetonide Cream USP, 0.025% 15 grams WARNING: Keep out of reach of children For External Use Only Not for Ophthalmic Use USUAL DOSAGE: 2 or 4 applications daily. See package insert for full prescribing information. See end of carton for batch number and expiration date.
Each gram contains 0.25 mg triamcinolone acetonide USP in a cream base consisting of purified water, emulsifying wax, mineral oil, propylene glycol, sorbitol solution, cetyl palmitate, sorbic acid, and potassium sorbate. Directions for puncturing seal: Remove cap. Turn cap upside down and place puncture tip onto tube seal; push down until seal is punctured.
Screw cap back on to close IMPORTANT: Do not use if seal has been punctured or is not visible. Store at 20 o -25 o C (68 o -77 o F) [see USP Controlled Room Temperature] Avoid excessive heat. Protect from freezing.
Manufactured and Distributed by: Crown Laboratories, Inc., Johnson City, TN 37604 0.025% Carton
Triderm… [Excerpted — this section continues on DailyMed.]
Medicare Part D spend CMS · PART D · 2026 (Q1)
About this NDC listing & data coverage
What data is (and isn’t) available for this NDC — tap to expand
| NDC identity (package / product / labeler codes) | ✓ Available |
| Labeler | ✓ Available |
| Product & package description | ✓ Available |
| Marketing category & status | ✓ Available |
| Active ingredient / dosage form / route | ✓ Available |
| FDA label (SPL via DailyMed) | ✓ Available |
| Package photos | ✓ Available |
| Inactive ingredients (structured) | ✓ Available |
| NADAC pharmacy acquisition price (CMS) | — Not published for this NDC CMS publishes NADAC only for NDCs reported in its retail-pharmacy survey. |
| Orange Book / therapeutic-equivalence data | ✓ Available |
| HCPCS J-code billing crosswalk | — Not published for this NDC Most self-administered / retail products have no J-code — that is normal. |
| Medicaid utilization (CMS SDUD) | — Not published for this NDC CMS reports utilization only for NDCs with Medicaid claims above its privacy threshold. |